Quintrio
Home

Stock overview

PRF Technologies Ltd. Ordinary Shares

PRFX

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.662 – $0.737
Volume 7,511
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PRFX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PRFX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial

PRF Technologies announced FDA clearance of its Investigational New Drug (IND) application for OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract surgery pain and inflammation. The company plans to initiate a Phase II clinical trial in the United States with patient enrollment expected in the second half of 2026. OcuRing™-K aims to eliminate the need for complex post-surgical eye-drop regimens by providing sustained, localized drug release through a single intraoperative application.

Benzinga

What's Going On With Pharma Company PRF Technologies On Tuesday?

PRF Technologies (NASDAQ: PRFX) shares tumbled on Tuesday as the broader market traded lower and investors digested the company's year-end business update. The stock, down 76.25% over the past 12 months, continues to face headwinds despite the company's strategic repositioning into a diversified platform spanning specialty pharmaceuticals and AI-driven solar analytics. Key 2025 initiatives included a majority investment in LayerBio for ocular drug delivery and the acquisition of DeepSolar for solar analytics, but traders remain skeptical of converting these initiatives into sustainable revenue.

GlobeNewswire Inc.

PainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

PainReform's DeepSolar business unit launched Smart TDD, an advanced solar Technical Due Diligence service designed to provide faster and more comprehensive assessments of solar asset performance. The service targets the $60+ billion annual solar asset M&A market by offering complete data coverage, AI-driven diagnostics, and rapid turnaround to support investors, operators, insurers, and lenders across the solar asset lifecycle.

Benzinga

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

BladeRanger (TASE: BLRN), a drone-based inspection and AI analytics provider for green energy infrastructure, will showcase its Solar Drone and DeepSolar platforms at Abu Dhabi Sustainability Week. The company is expanding its regional presence in the UAE, where $600 billion is being invested in hyperscale data centers and renewable energy systems. BladeRanger has held strategic meetings with major regional energy organizations including ADNOC, TAQA, and Masdar.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 6, 20261-for-5reverse split
Nov 21, 20241-for-4reverse split
Sep 9, 20241-for-6reverse split
Jul 3, 20231-for-10reverse split